Harrow, Inc. (HROW) Earnings Call Transcript & Summary
March 3, 2026
Earnings Call Speaker Segments
Michael D. Biega
executiveHello, everyone, and thanks for joining us for Harrow Health, Inc.'s call covering results from the fourth quarter and the entire 2025 fiscal year. I'm Michael D. Biega, serving as Vice President of Investor Relations and Communications, and it's a pleasure to welcome you to this discussion. Statements made by the company today could contain forward-looking language as defined under federal securities laws. Such forward-looking statements carry many risks and uncertainties, a great number of which lie outside Harrow Health, Inc.'s ability to control, among them the risks and uncertainties outlined periodically in its SEC filings, for example those tied to the company's capacity to bring its FDA-approved products along with compounded formulations and technologies to market, and to secure FDA approval for specific drug candidates either promptly or ever; for a full list and description of these risks and uncertainties, please refer to the Risk Factors section in the company's latest annual report on Form 10-K submitted to the Securities and Exchange Commission. Actual results for Harrow Health, Inc. could differ materially from what has been projected. Harrow Health, Inc. makes no commitment and assumes no obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events, or otherwise. The information shared on this conference call is time-sensitive and holds accuracy only as of today. Also with me on today's call are Mark L. Baum, our Chief Executive Officer, Andrew R. Boll, President and Chief Financial Officer, Patrick Sullivan, Chief Commercial Officer, and Amir Shojaei, Chief Scientific Officer. Now I'll hand things over to Mark. Mark.
Mark L. Baum
executiveGood morning, and thanks for being here with us. Harrow Health, Inc. has gone through a fundamental transformation across the last 5 years. Today, Harrow Health, Inc. holds one of the biggest portfolios of prescription ophthalmic products available in the United States market. When it comes to ophthalmic pharmaceutical products in the U.S. market, no one has acquired more than we have, with over a half a dozen transactions completed and more than 15 branded products brought into our scalable commercial platform, which reaches every populated county across the United States and has an impact on nearly every key ophthalmic disease segment. In my letter to stockholders, you'll notice I express pride in something: across the past 5 years, hundreds of members of the Harrow Health, Inc. family—among them my incredible leadership team—achieved genuine economic results and built stockholder value, which drove the Harrow Health, Inc. stock price up by more than 700% during that stretch. As a founder and a significant Harrow Health, Inc. shareholder, I feel proud of our track record, as well as of the returns we deliver to stockholders patient enough to let this team do its thing. This team isn't done, and honestly, we have only just begun. I can't promise you where our share price is going to be five years down the road. That said, I'm about as close to certain as anyone can be that Harrow Health, Inc. is going to grow into a larger, stronger company that makes a real difference for millions of people across America. It's my strong conviction that by that point, we'll be moving greater volumes of every one of our major offerings — VEVYE, IHEEZO, and TRIESENCE among them. I expect we'll also sell a lot more of several other items that a great many shareholders haven't paid much attention to. On top of that, I expect us to close some very attractive deals to bring in new products and/or companies, with terms designed to strike the right balance between risk and upside. To wrap up, I feel very confident saying that a couple of the product candidates we picked up through the recent Melt Pharmaceuticals acquisition — the ones we're now referring to as G-MELT and YOCHIL — are going to get marketing approval. And assuming they receive the coding and reimbursement we anticipate, they'll deliver enormous gains to the standard of care in ocular surgery, and more broadly to the lives of a great many Americans who need something other than IV and opioid-based medicaments for sedation and anxiety. This is a really big market. Naturally, as I noted in my letter to stockholders, these assets ought to eventually turn into our biggest revenue products. I'd wager that if we accomplish all of that, and perhaps a bit extra on top, our patient shareholders ought to see substantial returns. I'd love for you to come along with me on this journey, since our finest moments are unquestionably still to come. Let me now give you some detail on where our business stands right now; we're moving into the last stage of the 5-year plan we're currently executing, and we're doing it with momentum behind us. Everything we've assembled — the portfolio, the pipeline we've advanced, and the commercial base we've built — was designed from the start with scale in mind. This isn't a company centered on a single product, nor a narrative about one product; we're diversified in a way that truly matters. Durability, operating leverage, and sustained growth are what our commercial platform is engineered for. As of today, Harrow Health, Inc. functions as a single Harrow Health, Inc. — one strategy, one commercial engine, one unified organization. What we've built is a diversified ophthalmic franchise centered on broadening patient access, making things more affordable, and producing strong clinical outcomes. During Q4 of 2025, that strategy received clear validation. All of our core growth drivers sped up at the same time for the first time. That alignment strengthens our confidence and backs our objective of surpassing $250 million in quarterly revenue by the close of 2027. On the financial side, 2025 was a solid year. We delivered strong growth at the top line along with operating leverage, and that really shows how much earning capability sits inside our business model once revenue grows. I want to spend a moment on a handful of main drivers. VEVYE is positioned for faster revenue and quickening momentum in new prescriptions. Broader payer coverage is now in place. To fully capture the chance to build a product whose peak sales could reach several times what we saw a year ago, we are bringing on twice as many people in the VEVYE sales organization. A bigger team of sales professionals will drive more prescriptions. That should turn into profitable revenue growth that keeps expanding. The data backs this up. On average, people with coverage are getting about nine refills each year, which works out to essentially twelve months of treatment, and that tells us demand for VEVYE is holding up strongly. With access continuing to widen and our commercial push gaining momentum, we anticipate prescription volumes will keep climbing throughout this year and well beyond, since VEVYE is at last on track to surpass $100 million in revenue during this year. IHEEZO posted its strongest quarter ever, driven by real momentum across a rising number of retina specialists' practices; by zeroing in on procedures performed in the office, we've expanded the market we can reach, lifting our procedural volume TAM by more than 2.5 million units per year; we also expect pricing gains for IHEEZO beginning in this year's second half, when we introduce a new packaging format designed for retina. At roughly the same point, we anticipate that results coming in from studies focused on the retina will show, as patients experience it, what sets IHEEZO apart from older anesthesia approaches; our view is that this can only work in our favor; the data still has to tell us; those efforts during 2026 ought to drive additional gains on the financial side. Now that several avenues for growth exist, IHEEZO stands as a lasting and essential component of our strategy for the long run. TRIESENCE had its best quarter since it was brought back to market, which shows uptake picking up speed within the enormous ocular inflammation sector. Looking at what this quarter has shown me — new account trials getting underway at a bunch of accounts that could turn out to be really big, plus rising confidence around market access — I've gone to our talent team and asked them to at least double the sales force dedicated to TRIESENCE, so we can push deeper into what is still a very large market. The early indicators are only now beginning to appear, but they look meaningful. Because of where this revenue is generated, the odds are good that it persists well as time goes on. Getting a product like TRIESENCE written into a surgical treatment protocol is not an easy thing to accomplish. After that happens — and I've witnessed it repeatedly throughout my career — should the product produce outstanding results, which TRIESENCE seems to be doing, surgeons tend to resist switching; that's my point about how durable the TRIESENCE momentum is; along similar lines, I've discussed for a long while keeping tabs on where top-tier sales representatives move. That's about as close to a guaranteed forward-looking signal of upcoming success as you'll find. After all, sales reps head toward places where they can succeed, earn well, and support themselves along with their families. So word is spreading that TRIESENCE has real momentum; these top reps nationwide are learning about how dedicated we are to this product, and they're aware that they'd be selling the G-MELT as well should they secure a spot on our team. Plenty of people are eager to get involved with the G-MELT, I can tell you.
Mark L. Baum
executiveAlright, we're witnessing an explosion of incoming interest from several of the most accomplished pharmaceutical reps in eye surgery who are eager to fill those highly sought-after surgical roles with Harrow Health, Inc. on the TRIESENCE team. That's genuinely encouraging. Now, moving along to our rare specialty and compounded products. Believe it or not, behind the scenes we've been putting together some pleasant surprises for our stockholders. From the area of our portfolio they'd likely least anticipate. That's right, our rare specialty and compounded products. This portfolio has just come under fresh sales leadership, and it's going to gain from additional resources we're allocating to at last extract the value we anticipate from this exciting and distinctive collection of products. As I covered in greater detail in my letter to stockholders, there are 3 products within this portfolio that our team has quietly been accomplishing excellent work on. One product is waiting on a coding determination from CMS, which we anticipate in April. There are no assurances, but should this come through next month, it will unlock a very appealing, attractive market for this product. With respect to another product in this portfolio, we have a pivotal study ongoing that we expect to report out later this year. Our whole team is tremendously excited about this opportunity; this one is significant. Based on what we understand about this product, we anticipate the study will be able to showcase the opportunity we have identified, and once the data is released, it ought to drive opening up, as I mentioned, a very substantial and compelling market for this product; in fact, we are concurrently resolving supply chain challenges to make sure that if things turn out the way we anticipate, that we can supply the market sufficiently given the historically lower volumes this product has demanded. There's a third product that we expect to be brought back from this portfolio to also serve yet another appealing but smaller market opportunity, though a good one nonetheless. The takeaway is that I believe our stockholders might be pleasantly surprised throughout the year and into next year as our plans for this portfolio become known. A few closing points. In 2026, we will also introduce two important products BYQLOVI and BYOOVIZ, further expanding our retina and specialty footprint and leveraging our commercial platform. Past commercialization, our pipeline keeps progressing, and Amir will soon discuss the excellent work he and his team are doing. In summary, Harrow Health, Inc. is a diversified ophthalmic platform with multiple accelerating growth drivers and increasing operating leverage; we have shown the ability to build, integrate, and grow, and generate one heck of a great return for our patient stockholders as our five-year track record illustrates. As I stated at the beginning, I truly believe we remain in the early innings of our growth and stockholder value creation story. Having said that, I'll hand it over to Andrew. Andrew?
Andrew R. Boll
executiveHi, everyone. To kick things off, I'll walk through how we performed financially in Q4 and across the whole of 2025. For the fourth quarter of 2025, consolidated revenues totaled $89.1 million, representing 33% growth compared with the same period a year earlier. When we look at the entire year, revenue got to $272 million, which is 36% higher than what we saw in 2024. Driving that increase was continued momentum throughout our branded portfolio, together with commercial execution that kept getting stronger, particularly in the back half of the year. On adjusted EBITDA, we posted $24.2 million during Q4, and $61.9 million for the full year, amounting to 54% growth year-over-year. That margin improvement demonstrates the operating leverage embedded in our model, since revenue grows at a faster pace than costs, all while we continue putting money into commercialization and R&D. On top of that, operations brought in a bit less than $44 million of cash across 2025, and that let us close out the year holding $72.9 million in cash and cash equivalents. Taking it all together, 2025 stood out as a period defined by solid execution, better profitability, and capital deployed with discipline. Let's now turn to the main engines of our growth. Starting with BYOOVIZ, Q4 revenue came to $25.9 million, a 14% sequential gain, which lifted the full-year figure to $88.7 million — a 216% jump compared with 2024. Underlying that expansion is growing demand. As for IHEEZO, it generated $35.9 million in Q4 and $81.3 million across the full year, equal to 64% growth versus the prior quarter and 65% growth versus the prior year. Driving that result was deeper penetration among both newly added and long-standing accounts, especially within Retina. Because of how TRIESENCE is performing and the smaller bets we intend to make in that area, we're breaking out this revenue line on its own for the first time. TRIESENCE brought in $5.1 million during the fourth quarter, which is 36% higher than the third quarter, and reached $9.9 million across the full year, up 193% compared with 2024. Faster uptake of TRIESENCE and ocular inflammation largely fueled that expansion. Our rare specialty and compounded portfolio came to $22.2 million in Q4 and $92.3 million for the entire year. The short-term compounding supply limitation we mentioned three months ago should be worked out within the next few weeks, and we anticipate that inventory will return to normal levels around the close of the first quarter. We don't expect this problem to happen again. As we move into 2026, we're taking a more transparent and structured approach to guidance, and we're dedicated to giving you a clearer picture of our business's seasonality and how we see performance developing over the course of the year. Our full year 2026 revenue projection is somewhere between $350 million and $365 million. When it comes to modeling, our current expectation is that first half revenue will land in the range of $133 million to $153 million, while second half revenue should fall in the range of $203 million to $226 million, which mirrors the anticipated phasing of demand, channel dynamics, and launch timing throughout the year. For the entire year, we're projecting adjusted EBITDA somewhere in the range of $80 million to $100 million, and most of that EBITDA will come during the back half of 2026. Just like we've seen in previous years, the latter portion of the year should be stronger, and in 2026 that tilt will be even more noticeable. Revenue by quarter has traditionally followed a steady pattern, but 2026 will lean a bit more toward the second half. We expect Q1 to generate lower revenue than any other quarter, same as what happened in each of the past 2 years. That's primarily because of Q4 stocking activity, insurance resets, and a larger portion of plans carrying high deductibles. We figured that demand for IHEEZO in Q4 led to roughly 1.5 quarters' worth of extra inventory accumulating throughout the channel, and most of that stock should be used up in Q1. So even though demand for IHEEZO is rising much as it did in Q1 of 2025, the fact that we're working through the channel inventory from Q4 2025 means we don't expect IHEEZO to bring in significant revenue during Q1. VEVYE began this year with broader coverage that took effect on January 1. We think better access will keep pushing prescription growth higher as the year goes on, but Q1 usually brings a larger mix of high-deductible plans, which puts short-term strain on VEVYE and the rest of our branded portfolio. The coverage gain's financial benefit will become more noticeable later in the year, once our bigger sales force is completely in place. Our usual style is to spend in a disciplined, methodical way, and there's a reason we've done so: safeguarding profitability, generating ROI, and keeping cash flow robust. Even so, in 2025 we have a clear opening to maintain that same tight cost control while simultaneously accelerating how quickly we invest and how much we put in, which should expand the revenue foundation we build on going forward. As a result, we expect SG&A to land in the range of roughly $185 million to $205 million, up from what we spent a year ago, driven by expansion of our sales team around our core products and categories, including VEVYE and TRIESENCE, plus preparations to support the BYOOVIZ and BYQLOVI launches. We intend to bring on about 100 additional sales roles over the first six months, and pair that hiring with increased spending on promotion and marketing to drive awareness, adoption, and durable growth during the latter half of the year and continuing into 2027. What matters is that even while investing, we'll keep controlling costs with close attention to profitability and cash flow, holding ourselves answerable for returns and adjusting spending as needed. We also anticipate R&D costs climbing this year to roughly $30 million-$35 million as we finish the studies needed for the product candidates' NDA submissions and put money into post-market studies that Amir will cover later. We believe these efforts can underpin near- and long-term growth across key products. Turning to Q2, we expect IHEEZO to drop pass-through status starting April 1, which will affect the ASC market. About 30% of 2025 units came from the ASC setting. Our retina pivot back in 2024 and the in-office expansion strategy we announced recently, which, as Mark mentioned, brought roughly 2.5 million annual procedures into our TAM, have been getting us ready for this shift. Continued retina growth plus in-office utilization should offset the ASC impact and eventually surpass it. Additionally, we intend to introduce BYQLOVI during the second quarter, and that should help drive additional expansion within our specialty portfolio. Now, turning to Q3. Normally, we do see a bit of a slowdown in late summer, since physicians, their teams, and patients are all taking time off. During the third quarter, we'll get the initial complete quarter of BYOOVIZ revenue, which ought to deliver additional growth. We also anticipate that IHEEZO will pick up some extra momentum as a product that pairs well with BYOOVIZ. From the start of Q3, we expect to begin seeing the effect of our enlarged, entirely deployed VEVYE and TRIESENCE sales team fueling growth across both products. Also starting in Q3, we anticipate a price increase for IHEEZO taking hold. Combine that with ongoing retina expansion and the in-office build-out, and we believe IHEEZO will deliver a robust second half of 2026 and set us up nicely for 2027. Q4 ought to stay our best quarter, fueled by demand trends, stocking patterns, and patients hitting their out-of-pocket caps. Lastly, as Mark noted in his letter, while we deliberately move compounded volume toward FDA-approved branded options, transferring revenue into our specialty portfolio, we anticipate compounded revenue of roughly $60 million-$65 million across the entire year, with Q1 being the weakest quarter as we finish exiting the last phases of the inventory shortage. To sum up, we foresee a weaker first half while we clear channel inventory, take in the ASC transition, and deal with seasonal deductible effects; during the second half, we anticipate significant acceleration stemming from an entirely deployed VEVYE and TRIESENCE sales team, contributions from BYOOVIZ and BYQLOVI, better IHEEZO pricing, growing retina and in-office adoption, plus additional contribution from specialty products. I'll now hand the call over to Pat Sullivan.
Patrick Sullivan
executiveThanks, Andrew. Let's begin with VEVYE. We closed out 2025 carrying significant momentum from the fourth quarter, sitting at a distinct turning point now that broader coverage has kicked in. Even with only partial coverage during 2025, the number of prescribers writing VEVYE rose by 115%, which speaks to the robust demand underlying this product. The U.S. dry eye market is large and still expanding, so there is far more room for VEVYE to grow. Now that wider coverage is available and our sales force buildout is in motion, we anticipate that prescriber growth will keep going. Matching the data we shared in 2024, patients with coverage averaged roughly nine refills during 2025, which amounts to essentially a complete year of therapy. That degree of persistence highlights what sets VEVYE apart clinically: fast onset, lasting efficacy, and a comfortable feel on the eye without the stinging and burning that typically come with other treatments. The key point, however, is our belief that no other product in this category achieves this kind of refill persistence. Since we began expanding coverage, new prescription trends have accelerated, even as we worked through a difficult stretch with insurance benefits resetting and high deductible plans. We anticipate further gains as the year moves forward. To capture this opportunity fully, we are still on schedule to double the Veeva sales force by Memorial Day, growing our Veeva footprint among eye care professionals so we can push prescription volume higher throughout 2026. Now on to IHEEZO. In 2025, this product significantly exceeded what we had expected, delivering a remarkable 56% year-over-year increase in unit demand. That growth came from our expansion into additional retina practices and from deeper use within accounts we already had. The number of ordering accounts grew 49% compared to the prior year. Retina specialists accounted for roughly 70% of unit volume in the fourth quarter, which shows where adoption and clinical traction are strongest. Importantly, we think we remain in the early stages of penetration, with considerable untapped market opportunity ahead as we keep expanding utilization and driving wider adoption. Looking forward, during the second half of 2026, we anticipate a net price improvement, which we believe will further strengthen the product's revenue and overall financial profile. Importantly, this arrives as we get ready to launch BYOOVIZ in mid-2026, which will further speed IHEEZO's expansion into new retina accounts while deepening penetration within our existing customer base; we are also broadening IHEEZO into the office-based setting to extend utilization beyond retina; this effort targets over 2.5 million anesthesia relevant procedures that already benefit from established reimbursement pathways, which lowers access friction. Now turning to TRIESENCE, we posted a record quarter fueled by accelerating momentum in ocular inflammation and ongoing strength in retina. Even though we officially launched in market on October 1, a meaningful share of Q4 unit volume came from ocular surgery accounts; we expect this large market will generate most of the new volume going forward. Close to half of the fourth quarter ordering accounts were new, and they helped fuel quarter-over-quarter growth in unit volume. To build on this trajectory, we are currently in the process of doubling the dedicated TRIESENCE sales force. Given current trends, we see substantial runway for continued growth in 2026 and beyond. To wrap up, our rare specialty and compounded portfolio turned in a stronger fourth quarter, with fresh commercial leadership in place and better execution. That momentum is encouraging, yet in my view there is plenty of runway to expand this collection of everyday workforce products beyond where share stands today. Tied to these assets, we have a number of revenue generating initiatives underway, and we intend to lay those out in greater detail later in the year. At the same time, as Mark wrote in his letter, our attention is on turning compounded utilization into FDA-approved branded products by bringing PharmaPack Max and PharmaPack Prime to market, which further bolsters the long-term revenue profile for this segment. To close, all of our core growth drivers picked up speed in the fourth quarter, and we came into 2026 carrying obvious commercial momentum. We are growing the organization to keep pace with that trajectory — doubling the sales forces behind VEVYE and TRIESENCE, bringing IHEEZO into the office-based setting, and getting ready for significant launches during the year. Given stronger infrastructure, wider access, and a diversified ophthalmic portfolio, we feel we are positioned well to generate sustained growth and hand more value to patients and shareholders. On that note, I will pass things to Amir.
Amir Shojaei
executiveThanks, Pat. Now I'd like to discuss our pipeline, something we see as a strong driver of value over the long term for Harrow Health, Inc. This next stage of growth is tightly focused and efficient with capital; we're moving forward with clinically relevant programs that address clear unmet needs in ophthalmology and are closely tied to our commercial setup and regulatory know-how. There are a number of programs on this slide, plus others you haven't heard about yet, but today I'll only cover G-MELT, which used to be called MELT-300, along with the ongoing IHEEZO study. G-MELT really illustrates the way we do things. This is a procedural sedation prospect that contains no opioids at all and reduces the need for IVs, and it has the ability to change what the standard of care looks like in that space—personally, I think it may end up being the largest product we have. Today, procedural sedation generally requires IV access and depends on regimens built around opioids, which introduces complexity, adds demands on staffing, creates monitoring obligations, and extends how long recovery takes. With G-MELT, that model could become simpler. Regarding development, we kicked off the remaining pharmacokinetic work at the start of this year and are advancing CMC efforts alongside our CDMO partner; our plan to file an NDA in early 2027 has not changed, and we continue to explore options for accelerating the timelines. G-MELT strikes us as an opportunity at the platform level — a sedation approach that stands apart and has the potential to drive broad gains in how efficiently procedures get done, while building substantial worth over time, first in ophthalmology and later in other areas. Additional pipeline worth stems from broadening the clinical evidence behind products we already sell, IHEEZO among them. I find it remarkable how effectively our people have advanced IHEEZO in retina, given that the data backing it came from cataract procedures. Having worked on treatments for the back of the eye myself, I understand that retina specialists—the main people using IHEEZO—expect to see detailed results tied to the specific procedures they perform with it, which means intravitreal injections. That's why we're putting money into generating clinical evidence, so we can back up stronger adoption, stand apart from alternatives, and cement our long-term position with doctors and payers alike. This slide focuses on IHEEZO, but we're doing comparable work throughout the rest of the portfolio. Solid, high-quality evidence gives clinicians confidence, increases usage, and makes ongoing reinvestment in the franchise possible. When it comes to IHEEZO, we're funding several studies that complement one another in intravitreal injection procedures. The earliest data we expect, and the most imminent, comes from a randomized trial started by an investigator and headed by Dr. Sabin Dang is drawing a comparison between IHEEZO and the usual ways of delivering anesthesia, looking at discomfort and eye-related symptoms, and we should have those results when ASRS meets this coming July. The quote he gave us appears at the lower left portion of the slide. Turning to the IHEEZO trial that Harrow Health, Inc. is funding itself, my team designed a Phase 4 randomized multicenter study that measures safety along with pain as reported by patients, enrolling roughly 240 individuals. Enrollment got underway during the first quarter of 2026, operating under the IND, and we anticipate that findings will be in hand before 2026 comes to a close. Taken as a whole, these trials aim to produce evidence that carries clinical weight and speaks directly to practice, which should encourage wider and deeper uptake and cement IHEEZO's role as a lasting contributor to long-term growth. To wrap up, the pipeline at Harrow Health, Inc. is tightly focused, runs efficiently, and delivers real impact; it backs up the momentum we have on the commercial side, widens the markets we can reach, and opens up several routes to build value over the long term. What we are constructing goes beyond single products — it is an innovation engine that lasts, one that puts Harrow Health, Inc. in position to keep growing. On that note, I will hand things over for questions.
Chase Knickerbocker
analystMorning, everyone. I really value the honest perspective shared in the shareholder letter, and I appreciate you fielding our questions today. Mark, in that letter you noted that you anticipate ongoing expansion on the commercial side and better commercial mix for VVI throughout the year. From a commercial mix standpoint, what have you observed in Q1 so far? Could you take us through your ASP assumptions or the expected direction of ASP for VVI in the 2026 guide relative to volume? Thank you.
Mark L. Baum
executiveSure. On ASP, let me handle the second question first. When it comes to ASP and net pricing, the sole remark we have provided — and the only one we plan to provide — concerns the buoyancy and modest increase in ASP, which I had projected roughly a quarter or two behind schedule. Even so, as I wrote in the letter to stockholders, we recognized that trajectory and ultimately arrived there. With net pricing for VVI that is both more sustainable and buoyant, combined with certain developments we are observing commercially tied to this new coverage, we have launched a program aimed at more than doubling the VVI sales force. As for the build and what we are witnessing on the ground right now for VEVYE, as I likewise noted in the letter to stockholders, we began to detect a bit of accumulating momentum even during the fourth quarter. I believe I have mentioned previously that CVS had in fact distributed letters to many thousands of eyecare professionals across the United States, informing them about the new positioning — the preferred positioning — for VEVYE on its formulary. That by itself, I think, set in motion the positive momentum we are also observing somewhat in the first quarter. What I can tell you about the first quarter is that it is generally a softer stretch, and we are fairly surprised by the new prescription volumes we are currently seeing compared with what we had expected, meaning those new prescription volumes are considerably stronger than what we had anticipated receiving at this stage of the year; we expect that to grow as the year goes on. As I stated in my prepared remarks, we possess data showing quite clearly that having additional reps in the field for this specific product — given how persistent the product is and the market's interest in it — produces more prescriptions; for us, generating those new prescriptions ultimately results in ever-growing total prescriptions and greater revenue. We are focused on growing volume in VEVYE, that is the way we are positioned for this year, and that is what you ought to expect.
Chase Knickerbocker
analystThat's helpful, Mark. For my follow-up, I have another multi-part question, this one about the TRIESENCE Phase 3 cataract program you announced this morning. Clearly, that represents a sizable potential volume opportunity. A few questions, then, to help us gauge how big this could be. As far as the cataract market goes, which percentage would you describe as the sweet spot for TRIESENCE, considering how its value proposition stacks up against the multi-drop regimens that remain so widespread today? And how should investors frame the TAM expansion that comes with this label expansion in cataract for TRIESENCE? Second, I think investors frequently wonder about how long the opportunity lasts for pass-through products in the ASC. Could you remind us, or walk us through, what makes TRIESENCE unique in a way that might permit payment over a longer term outside the bundle, or explain your planned approach to pricing there?
Mark L. Baum
executiveSure. Once again, I'll address the second question, meaning the latter part, first. When it comes to reimbursement for this product, TRIESENCE carries a very distinctive label, since it is used both in the office setting of care and in the hospital and outpatient department setting of care. Because of that — and I don't want to get into the nuances of reimbursement policy — we believe TRIESENCE won't be constrained by a TPT or a temporary pass-through period. Now for the first part of the question, regarding what the TAM expansion could be for this study that Amir just received clearance on, I believe, yesterday. I'll return to something I think I said earlier in my prepared remarks: our vision for cataract surgery is that going forward, patients in the United States ought to have a procedure that is IV-free, opioid-free, and even eye drop-free. That's what I'd want my mother to have; that's what I'd want anyone I love to have. Not having to put drops in their eye several times per day, from several different eye drop bottles — assuming, of course, that you're using an FDA-approved product. That ought to be the ideal, and that's what we're working toward. That's what the G-MELT is about, and that's what this expansion with TRIESENCE is about. It's about giving the surgeon the power to deliver the anti-inflammatory into the eye, so the patient doesn't need to administer those post-surgical eye drops. What's interesting is that, anecdotally, we observe that among patients using this on label — which is a subsegment of the cataract surgery population — it's those patients who truly cannot administer eye drops, who have other comorbidities. Because those patients are achieving such exceptional results, we decided to invest in expanding the label so that every cataract surgery patient has access to this therapy. As I mentioned, the fact that we now have reimbursement is fantastic. Our clinical results are outstanding; through the remarkable trial that Amir and his colleagues are about to carry out, we will secure a label with very wide coverage, which will at last allow cataract surgeons to obtain an anti-inflammatory for use after cataract surgery that is simple to give, extremely effective, and injectable by the surgeons themselves. Now here's what's best for patients and consumers: among all injectable steroids, it carries the smallest out-of-pocket cost, roughly $37 for each unit. It's within reach financially, it's obtainable, it works extremely well, and we will put a quite modest sum of money into a study that meaningfully grows the pool of patients able to get it; within the United States, when this data becomes available, that figure ought to reach approximately 5 million procedures every year; the market opportunity is enormous. For 2 years now, as I've been saying, TRIESENCE grows slowly. Certainly, we still have much to demonstrate there, yet over the coming 2 years this product is going to become a significant source of value for those who hold our stock.
Chase Knickerbocker
analystThat's really useful, Mark. Thanks a lot.
Timur Ivannikov
analystYeah, hello, and thanks. Timur Ivannikov here, filling in for Steven Seedhouse. To start with IHEEZO, I believe you brought up price improvements during the second half of 2026. Can you make that clearer — does that price improvement come relative to Q2 2026, or relative to Q4 2025? And are you expecting the Q2 2026 ASP to be significantly lower? Thank you.
Mark L. Baum
executiveAndrew, would you like to handle that?
Andrew R. Boll
executiveRight, let me just make sure I give you a proper answer here. Our expectation is that once we reach the third quarter of 2026, the pricing situation for IHEEZO will have improved compared with 2025 as well as the early portion of 2026.
Timur Ivannikov
analystAlright. Alright, I understand. The next thing I'd like to ask concerns how the TRIESENCE cataract study is put together. My aim was just to get a clearer picture of that trial. I believe you brought up the comparison against placebo in its design. Would you mind addressing whether anti-inflammatory eye droplets get used in each of the arms? What I'm getting at is, is it permitted to administer those droplets both to the arm receiving treatment and to the control arm? Thanks.
Mark L. Baum
executiveAmir, could you take that question?
Amir Shojaei
executiveYes, hello. The way the protocol is structured seems quite straightforward, in my view. There will be a control group that does not receive TRIESENCE. What we already have in place are rescue criteria. Under the protocol, those rescue criteria would permit drops once more.
Timur Ivannikov
analystAll right. Thank you. I appreciate it.
Mayank Mamtani
analystGood morning, everyone. Thanks for fielding the questions, and we appreciate the useful forward-looking guidance framework. Regarding VEVYE, NRX is getting better and the commercial mix is improving as well. Mark, could you tell us about any market share targets you might have for the end of the year or the second half, so we can get a sense of the market's growth? Clearly, several companies are putting money into the penetration side, but we also want to hear how you view share gains in both the cash pay market and, of course, the commercial mix market. I have a follow-up about IHEEZO.
Mark L. Baum
executiveSure. Yeah. For VEVYE, we have 3 goals. To start, I want to mention that as Pat said, the dry eye market in the U.S. is a very large market. Our view is that it remains under-penetrated, and we keep seeing data showing that large portions of the dry eye patient population are getting products every month that burn and sting, cause pain, sneeze. Honestly, the list of these effects goes on too long. When we observe patients obtaining these suboptimal therapies, for whatever reason, whether that is coverage or simply because they do not know about VEVYE, we view that as a chance to switch those patients to a therapy that does not burn and sting and that provides all the positive benefits VEVYE has, including these improved coverage metrics we now have. As for our goals, to be clear, the first one is our belief that VEVYE will become the number one cyclosporine in the U.S. market. Cyclosporine is the most trusted active ingredient in the dry eye market, and our aim is to be the top cyclosporine. Next, we believe we can capture the anti-inflammatory market, meaning any product that actually contains an active ingredient that would be an anti-inflammatory. Our view is that all forms of dry eye disease, we do not care which one you pick, have an inflammatory component. Our aim is to be, secondarily, the top anti-inflammatory. Eventually, and this will not happen overnight, we think this particular product gives us the opportunity to become the number one most prescribed dry eye product. Over the last couple of years, our competition has had a sales organization where even the weakest products on the market have had far bigger sales organizations than ours; as I mentioned, we are now more than doubling our sales force. I think we are over halfway there. Actually, I am surprised. The talent team is doing a great job. There are simply a lot of people who want to join Maria's team and sell VEVYE. When it comes to specific market share percentages, we are not providing those goals. My take is that to become the leading cyclosporine in the market, we likely need a share just above 20%. That should give you an idea of what we view as within reach. Incidentally, we already hold that position in quite a few markets. The issue is that historically we reached so few markets with a sales team of slightly fewer than 50 people that even when you hold better than 20% share in the greater Cincinnati area, which is in fact the situation, you... In plenty of other markets, you simply don't have that level of share. Now, with this larger sales force, numbering nearly about 100, we'll reach more markets. I believe we'll grow our market share, and we'll move nearer and nearer to that objective of becoming the number one cyclosporine. Pat, would you like to add anything to that?
Patrick Sullivan
executiveAppreciate that, Mark. As we laid out in our earnings, one area giving us the most optimism is the pickup in prescriptions — writing grew 115% for us. Like Mark said, what we hear back from eye care professionals and the patients they treat has been overwhelmingly favorable, particularly regarding how VEVYE stands apart in controlling inflammation, the speed at which it takes effect, and its distinctive tolerability profile. That gives us a great deal of encouragement as we move into the next expansion phase, reaching a far bigger share of the market and boosting VEVYE's footprint so we can truly build this product into the leading cyclosporine. Mark, we're making strong progress toward establishing the next stage of growth for VEVYE.
Mayank Mamtani
analystRegarding IHEEZO, there's clearly plenty happening. The ASC pass-through status is expiring, yet you also brought up an improvement in price per unit. You also mentioned some data generation work at the ASRS conference halfway through the year. I was just wondering, to put its contribution to guidance in context — are you thinking of this like VEVYE, a contributor of 9 digits in revenue for this year, or is that a more sensible target for next year?
Mark L. Baum
executiveYeah, I don't want to speak about revenues for that product. The only product where we've provided specific guidance, I believe, is VEVYE, which is plainly, you know, headed toward nine figures. Here's what I'll say. As a reminder, during 2024, our retina presence was absolutely zero; no retina sales force existed for us. We had no offerings in that market at all. It was only a couple of years back that we brought that sales organization on board; in August of 2024, really, we started what we refer to as the Retina Pivot, through which we managed to draw excellent individuals away from far bigger companies with incredible retina credentials, and we assembled this organization. I recall attending ASRS in Stockholm. No one was familiar with Harrow Health, Inc. We had zero footprint in that market. The retina community is an extremely close-knit one. What I can share is that across the past year and a half, roughly two years, I believe that if you approach retina professionals today and ask whether Harrow Health, Inc. rings a bell, they genuinely do know Harrow Health, Inc. Another point I must make specifically about IHEEZO, since what Ali and her team have accomplished is remarkable. They took a product whose clinical studies backing the NDA were conducted in cataract surgery, and they've managed to adapt that data to the intravitreal injection market, with over 70% of IHEEZO's unit volume now sitting in the retina market. What's truly thrilling is what Amir discussed concerning the DANG study. What Ali has sought for well over a year — we've had countless conversations — is data specifically tied to how IHEEZO performs in the intravitreal injection procedure; we possessed all this anecdotal information, you know, physicians would describe its performance to us. You know, certain physicians experienced other advantages from the product, among them efficiency in their workflow. What I believe you'll witness midway through the year, at last, for Ali and her team, is a data set that will show the genuine distinction between IHEEZO and those legacy methods of delivering anesthesia to these patients for these intravitreal injections. I must tell you, if you're a patient receiving these injections, the anesthesia and pain control truly matter. From what we can tell, at least based on anecdotal reports, we've gotten an enormous amount of feedback from accounts using this product regarding how it performs; midway through the year at ASRS, and incidentally, he received a late breaker. Look, these aren't simple to obtain. He will be presenting that data, and my belief is it will drive considerable demand for this product within the retina market. Regarding how IHEEZO factors into our full-year guidance and definitely into 2027, it depends on what this data shows, but I see this as a chance to substantially boost unit volume demand for IHEEZO. As Andrew mentioned, that combined with the new packaging format designed specifically for retina and a significantly better price, I believe that by the close of next year, you'll hopefully be taken aback by what we believe we can produce from this specific product.
Mayank Mamtani
analystThanks, Mark. And then just one last thing, real quick — on that OpEx increase, you know, R&D came in bigger during the fourth quarter. Is that more of a first-half-weighted type of pattern? Or is it a level of OpEx spending, Andrew, that you're aiming to reach at some stage in the current year? Appreciate you taking my question.
Mark L. Baum
executiveThanks, Mike. Andrew, would you like to take the OpEx one?
Andrew R. Boll
executiveSure, Mike — thanks. First, I want to call out something in the Q4 P&L: there's an $8.5 million charge tied to acquired and processed R&D, and it relates to the Melt acquisition. That covers upfront costs along with certain transaction costs from the deal. Nothing from that acquisition cost was capitalized. Under GAAP rules, the whole amount flowed through the P&L and through R&D. Also, for the 2024 EBITDA figure, we didn't back it out — or add it back in, rather. Just wanted to flag that as we look ahead.
Mark L. Baum
executiveThe adjusted.
Andrew R. Boll
executiveThe adjusted EBITDA, pardon.
Mark L. Baum
executiveGo ahead.
Andrew R. Boll
executiveThe-
Mark L. Baum
executiveYeah.
Andrew R. Boll
executiveWhen we look ahead at OpEx, Mike, I'll split it into a couple of pieces. On the SG&A side, we're bringing on sales staff at this very moment. Through Q1 we've been hiring them at a fast clip. In Q2 we'll keep doing so; beyond that, we've been getting ready. From a marketing and promotion angle we're also preparing, and that pushes the spend higher too. A good chunk of that is about getting out in front of things, so once those folks are onboarded and trained, they can immediately be productive with VEVYE. TRIESENCE as well, for that matter. On the R&D side, much of the expense, as you're aware, depends on the trials. We essentially have a baseline level of R&D spending compared with the prior year. With this morning's announcement that the TRIESENCE IND was accepted and that study getting underway, those costs will surface around the middle portion of the year, meaning Q2 and Q3. There will be somewhat of a build through the middle portion of the year, and afterward it ought to ease somewhat on the R&D side during Q4, as those studies plus certain Melt studies wind down.
Lachlan Hanbury-Brown
analystHi, everyone. Appreciate you taking our questions. So, first off, it would be helpful to get a bit more detail on your expectations for how IHEEZO will play out in 2026. You mentioned that expanding in-office procedures past retina could make up for what's lost in the ASC. Are you referring specifically to Q2 there, or do you mean over a longer horizon — say, roughly a year out — it will more than make up for that? And should we be anticipating a decline in unit demand during Q2?
Mark L. Baum
executiveI'd rather not get into specifics about demand for any given quarter, beyond saying that across Q4, Q1, Q2, and Q3, as I believe I've mentioned before, we anticipate demand will keep growing. Demand keeps growing. That's distinct from revenue recognition, but demand for the product does keep growing. As for when the offset from losing the ASC units is likely to show up: when I examined the ASC units specifically, the quantity of units we're losing compared with the total opportunity we're bringing in by adding these in-office opportunities — with this 2.5 million unit increase to our TAM — it represents such a tiny amount of success; we have a dedicated team calling on the very same customers who use it in the ASC but don't realize they can also use it in their clinics. Keep in mind, each doctor using it in the ASC is a surgeon. They also only spend a day or two each week in the surgical operating room. The remainder of the week, they're in their office performing procedures. It's a straightforward concept. We're approaching the same customers who are using the product satisfactorily in the ASC. We're telling them, "You perform more procedures in your office than you do in the, in the surgical suite." It's not applicable to every procedure, but for those procedures where this can have an impact, we're going to those same customers and attempting to convert their in-office business. It's such a small number of units, as I mentioned, that we don't need to be all that successful to completely offset everything we're losing when we lose the temporary pass-through code. Will that occur in the first quarter or the second quarter? No. I doubt it; it ought to occur throughout the year. As I said, it's such a small number of units relative to the overall opportunity that we can fail and fail and fail again and still wind up absorbing all of those lost units from the ASC.
Lachlan Hanbury-Brown
analystAll right. I appreciate that. Happy to have that cleared up. I suppose my follow-up concerns VEVYE and this additional coverage. I am curious about the kind of patients who are having prescriptions filled through that coverage. Are these patients who are new to the brand, or is there a meaningful portion of them who, you know, used to pay in cash or perhaps had coverage secured for them before and are now simply shifting over to, you know, a situation where they are covered with greater ease?
Mark L. Baum
executiveYes. I am unable to give you specifics in terms of figures, you know, the percentage or the count of patients making that conversion. You know, I can more or less repeat what we have communicated previously, which is that, you know, during 2025, a large number of patients had prescriptions written for them, you know, lawful prescriptions, yet they were refused access to the product for some reason or another, and they decided against filling their prescription. We are reaching out to those patients. Now, those patients continue to hold lawful prescriptions, and it is possible for us to get in touch with them and inform them that coverage now exists and attempt to win over as many of them as we can. Meanwhile, there are patients who are paying in cash, like you mentioned, so these consignment patients who currently have coverage but did not have it before, and we are able to approach them. We have precise knowledge of who those individuals are too and can convert them. This represents a substantial group of people and, you know, what you are referring to is, you know, considerably more than $30 million in newly covered lives where you have, you know, optimal access for VEVYE at this point; we need to observe how this unfolds. I believe given what we have observed during the first quarter, we assumed we would not be at this point; we are in a stronger position than we anticipated regarding new prescriptions. The new-to-brand aspect, I believe, will arrive once we have these additional individuals in place, these additional sales representatives. You will see an increasing amount of that new to brand. I can, I do not wish to take away Pat's moment, but Pat, would you like to actually address the entire new-to-brand situation? I am aware that has truly been something you have concentrated on.
Patrick Sullivan
executiveAppreciate that, Mark. So, when I look at where VEVYE goes in its next stage of growth, the heart of it really comes down to generating fresh momentum for VEVYE. As Mark said, we're aware that better outcomes are achievable in dry eye disease management. Going forward, our primary objective is essentially to capture patients who are new to the brand. That, I believe, will be a major area of emphasis for us. Clearly, at the start of this year, as we made the switch from CVS, we were right in the middle of our expansion — and in the run-up to it, we concentrated heavily on identifying the right patient and collaborating with our physicians, along with how we communicate, to ensure we're going after those patients. That's because we understand that for people either walking in with dry eye disease symptoms or dealing with symptoms that remain unresolved or persistent despite other treatments that aren't optimal, VEVYE is the ideal option. What we're aiming for going forward is to guarantee we have the proper presence with our customers and, in the end, go after the right patients. Mark, as you pointed out, new-to-brand is an enormous priority for us, and it will genuinely begin to take shape as we move into our next expansion phase.
Mark L. Baum
executiveGreat. Thank you.
Tom Shrader
analystMorning. Appreciate the updates. Quite an interesting moment; regarding the VEVYE sales team, once you've added more, how do you stack up against rivals such as Miebo? Would you be on level footing? Just a follow-up question about the melt franchise, are you still committed to a pair of products? The first one appears to be the larger one, it's the combo. Does what you know from compounding tell you there's genuinely a demand for a pair of products? Thank you.
Mark L. Baum
executiveYeah. Well, I'll handle the first one. When it comes to the VEVYE sales team, we don't have precise knowledge of how many reps these rivals actually field. We've been told that one competitor holding a fairly substantial share of the market has 300 or more people. We'll have roughly 100 of our own. What I can share is that our reps are so effective that a single Harrow Health, Inc. rep selling VEVYE matches 4 of theirs. Just joking. We truly possess a fantastic sales force that's well trained, and they've got a superb product to offer. This marks the second stage of our build-out; this, we did the first round of hiring for this product. This is stage two, bringing us to approximately 100 territories or thereabouts. There could quite possibly be a modest bump in territory count once we witness this investment delivering returns. We're thrilled to have these, this sales team more than doubling shortly. I'm also happy with the caliber of individuals we've managed to bring in, and those we've kept on who are part of Maria's team. As for melt and whether both products are needed, the MKO Melt, a compounded formulation we've offered for several years, has truly shaped the whole development effort. One benefit of the G-MELT once it gains approval is that we'll stop making the compounded version, and we'll ideally shift all that business into, an FDA-cleared and ideally reimbursable offering. It's extremely difficult, as I've noted through the years, to move compounded drugs. They lack FDA approval; no label exists, especially in anesthesia and sedation, where an anesthesia professional will think two or three times before deciding to use a compounded formulation. Once we have an on-label FDA-approved product that's also ideally covered by reimbursement, this ought to greatly grow the market potential for the G-MELT in cataract surgery, and also for other procedures where a sublingual non-opioid sedation option can succeed. So why do we also need the 210 program? Well, 210 targets a separate market segment. Hard as it may be to believe, when you look at the overall unit opportunity for it — this is based on the expected label, and we still have to talk that through with the FDA and settle on what a label for what's currently known as YOCHIL would finally look like — that product's unit demand, in terms of volume, we think is larger than even the G-MELT. The G-MELT will definitely be used in cataract surgery, which is the indication we're studying. We also think it will be used the way the compounded product is in ENT and, you know, for endoscopy. It gets used in dermatology, plastics, dental — widely used in dental — and it's used for claustrophobia in MRI tubes; that's the experience we've had with the compounded version, the MKO Melt. Our expectation is that once approved, the G-MELT will eventually find use in markets beyond ophthalmology, and those are actually larger markets than the ophthalmic one. So the answer is yes, we need two products; they serve different markets. One relates specifically to anxiety. As I mentioned, it will also be available. I believe I said this in the letter to stockholders — ultimately it will be available in a number of different strengths.
Tom Shrader
analystLet me try to slip in a quick follow-up if I can. About the new TRIESENCE — it looks like a product that's far simpler both to manufacture and to administer. Would you consider taking it beyond ophthalmology, to the other areas where that steroid gets used, or is this strictly an eye formulation?
Mark L. Baum
executiveIt's strictly for the eye. As you know, our company got started back in 2014. Triamcinolone acetonide for injection was what we first sold. That active ingredient and that product category are things we understand extremely well. Our compounded formulation — again, what drives our excitement about TRIESENCE is the know-how we gained from selling Tri-Moxi across well over 1 million cataract surgery procedures. This is a market we understand thoroughly. It's simply that this particular product will only be for the eye. Still, we hold genuine high hopes of building that protocol once more — one that's IV-free, opioid-free, and eventually even eye-drop-free for cataract surgery patients — because that's truly where this market has to head.
Tom Shrader
analystExcellent. I appreciate all the detail.
Mark L. Baum
executiveYou're welcome, Tom.
Thomas Slayton
analystMorning, everyone. Thanks for letting me ask. To build on what we discussed about VEVYE, regarding growing the sales team, could you say a bit more — and Mark, I believe you touched on this — that much of it involves fresh regions, but is that fresh regions rather than dividing existing areas because of too much workload, and then how do you expect the interplay between the ophthalmology and optometry communities to factor into that expansion?
Mark L. Baum
executiveI will address the latter point first, and then hand the former over to Pat. Regarding the sales force — actually, forgive me. I do not. Your second sales force expansion and what else, Thomas?
Thomas Slayton
analystthe split between ophthalmology and optometry.
Mark L. Baum
executiveMark L. Baum, answer: Right. Ophthalmology. Yes. Ophthalmology as well as optometry — strange as it may sound — the optometric sector matters a great deal. I'd put it this way: I might lean just a bit in favor of the optometric sector. These days, I believe optometrists are prescribing dry eye drugs in numbers equal to, and perhaps exceeding, ophthalmologists. That's what the figures I've been reviewing indicate. Pat, would you like to address the sales force expansion in particular?
Patrick Sullivan
executiveYes. Thank you, Mark. When we consider growth, this presents a tremendous chance for us to reflect on the impressive results VEVYE has achieved for patients dealing with dry eye disease so far. One of the initial steps we take involves looking at this—regarding what you mentioned, you were discussing essentially business disruption as opposed to business continuity. It seemed your inquiry related to that. We are adopting a highly disciplined method to ensure that, first, we are reassessing to confirm that this strategy moving forward involves expanding the sales team, yet it centers on VEVYE's brand visibility and promotional effectiveness with our customers going forward. This is a highly vibrant category—it is big, expanding, and vibrant. As for us, similar to the earlier question from one of your peers regarding participating in that lively segment of the market where new-to-brand patients are, achieving that will require not just making our existing territories highly efficient, but also our expansions; we are being extremely, extremely careful in how we, first, assemble our footprint. The main point here is that VEVYE is set for considerable expansion moving forward, but it will hinge on how we, first, establish a fresh VEVYE presence before our customers. That aspect is, you know, truly about standing out, new-to-brand patients, and possessing the appropriate presence that matches being a top priority of becoming the leading cyclosporine and the leading dry eye disease therapy. Regarding your question, we are very deliberate about how we will propel that business to sustain our objectives and our growth moving forward.
Thomas Slayton
analystUnderstood.
Mark L. Baum
executiveThomas, speaking practically, what we need is for salespeople to be inside these offices. Their VEVYE reps have to be seen by them more often, and that's the point of all this. The high value targets are known to us. We know which physicians prescribe for dry eye disease. We know which ones are searching for dry eye disease. What this expansion does is let more Harrow Health, Inc. VEVYE reps enter those offices much more frequently. You know, our data shows quite clearly that doing so results in more VEVYE prescriptions. My belief is you'll witness that across the year.
Thomas Slayton
analystMark, following up on what was just said regarding MELT or MKO seeing heavy use beyond eye-related indications, what should we anticipate when it comes to striking deals so MELT gets properly capitalized on in those non-ophthalmology opportunities?
Mark L. Baum
executiveWell, at this moment our entire focus sits on 2 items. First is Amir alongside his group assembling that data set. I have placed a bounty on him submitting that NDA earlier than he himself believes possible. My hope is that we can, you know, perhaps beat a few of those timelines we've set out. Everything hinges on submitting the NDA and placing the data before the FDA so we can, hopefully, secure approval and afterward get it coded for reimbursement. Item two is that the market, even within ophthalmology, you know, involves at minimum 5 million use cases each year, and that figure covers only cataract surgery. Should you include glaucoma surgeries plus other relevant procedures, you know, another couple million procedures can be added. For a reimbursed non-opioid, non-IV sedation medicament, the ophthalmology opportunity is enormous. You know, it amounts to billions of dollars annually, with our competition being IVs and opioids. On the data side, a Duke study exists, a Mayo study exists, and the data is unambiguous. Today patients receive fentanyl doses for sedation, particularly during cataract surgery. Our goal is to alter that. We must construct our commercial strategy for the G-MELT, and that work is in progress, so that represents the second component. Beyond that, apart from the U.S. market in ophthalmology plus finishing the studies and filing the NDA, you know, if something emerges such as a partnership being disclosed or an opportunity of that nature being disclosed, we will definitely chase it. The revenue opportunity we have with the G-MELT in ophthalmology is so large that we truly must remain focused on it, and that is exactly what we intend to do.
Thomas Slayton
analystUnderstood. That's helpful. Thanks very much.
Jeffrey Cohen
analystHello there, good morning. We appreciate you fielding our questions. We have 2 things from our side, I suppose. First off, Mark or Andrew, might either of you offer any thoughts regarding margins and/or tariffs and the knock-on effects across 2026, or any net shifts you're currently observing relative to 25?
Mark L. Baum
executiveAndrew, would you like to take on tariffs and margins?
Andrew R. Boll
executiveRight. Hello there, Jeff.
Jeffrey Cohen
analystHi.
Andrew R. Boll
executiveSure, when it comes to tariffs, we don't anticipate a significant effect. The review we carried out in the prior year was, in a sense, nearly a worst-case situation at the time we took another look at everything, and we keep doing that on an ongoing basis. What we found in that review from the prior year remains solid, and in fact our position is stronger than it would have been a year ago under that worst-case situation surrounding Liberation Day. To address what you asked in a more straightforward way, we don't anticipate any effect on margins when it comes to tariffs in this year.
Jeffrey Cohen
analystUnderstood. And then, do you have anything to say about the BYOOVIZ launch you're expecting around the middle of the year — things like readiness and the commercial side, and what that could look like at midyear?
Mark L. Baum
executiveAndrew, would you like to speak to that? Is there anything you'd like to add? My sense is that we're set to move. My sense is that revenue starts coming in, and the team has a strategy that's quite distinctive. Andrew, would you like to speak to that, or Pat?
Andrew R. Boll
executiveI'll say a few words, then pass things over to Pat. Jeff, for this launch we're truly making use of the retina team that's already in place. Certain added expenses will be involved. As the hub gets stood up to back the product, we'll incur some variable costs too. Getting this effort underway has us genuinely enthusiastic. We also have an excellent collaborator in Samsung, assisting us as we get ready; this market is extremely fast-moving. With BYOOVIZ, a biosimilar referencing Lucentis, we'll be entering right away around the midpoint of this year. After that, you might have seen lately that Samsung said it had reached a settlement with the innovator drug for EYLEA. With that product too, we'll manage to reach the market somewhat sooner than we'd anticipated, at the start of next year, meaning January. On the spending side, as I mentioned, we'll draw on the bulk of the sales force we already have. A modest amount of added expense will show up there, plus possibly some variable costs tied to hub operations for the products, yet this ought to be strongly accretive to earnings on fresh revenues. Pat, is there anything you'd like to add?
Patrick Sullivan
executiveAppreciate that, Andrew. The main point I'd tack on is this: like Mark said, everyone here is genuinely thrilled to get moving on it. If you recall what Mark brought up regarding the group we've assembled, there's a really rich legacy in the retinal field. From my perspective, we're going to turn that into results fast. On top of that, looking at what we already sell, we've come a long way in expanding our retina operation, and this will give a big boost to our footprint while increasing what that franchise is worth. Right now we're busy getting the market ready and aiming our business to launch around the midpoint of this year. Honestly, we couldn't be more pumped about what BYOOVIZ can do down the road.
Jeffrey Cohen
analystExcellent. I appreciate your taking my questions.
Mark L. Baum
executiveThank you, Jeff.
Yi Chen
analystThanks for taking my questions. Could you share your thoughts on the marketing approach for the biosimilar — will there be a dedicated sales team, and how do you plan to position your biosimilar as distinct from the other biosimilar competitors? Thank you.
Mark L. Baum
executiveYes. Appreciate the question, Yi. As I believe Andrew mentioned and Pat talked about, as you're aware, this is a very dynamic market; it's competitive, and with our Lucentis referenced biosimilar, we hold a unique position in the market. Right now, I really don't want to disclose exactly how we're going to, you know, capture the market share we expect to drive toward. What I've stated before is that given our cost of entering into the deal, the amount of success we need in order to make this highly profitable is fairly low. We aren't aiming to capture 30% market share with BYOOVIZ; our aim is to capture a handful of percentage points of market share in this market, which is the largest market in ophthalmology by revenue. Our expectations are fairly modest, and we believe the strategy we're going to use, together with the team we have — which, as Pat said, has an incredible background in relationships — is going to succeed in helping us reach our goals; we don't have, you know, you know, we're trying to capture roughly a handful of percentage points of market share, which is what we've said historically.
Andrew R. Boll
executiveLet me jump in with a small addition as well. The single major edge we hold over all other players in this space is that we already have additional products going to those physicians. That lets us put forward a truly complete package. We're able to discuss what the patient goes through using our anesthetic. Nobody else in biosimilars carries that anesthetic. What we'll be offering goes well beyond biosimilar items alone; it's that full bundle of products through which we give the practice our complete backing, with attention centered on how the patient experiences everything.
Mark L. Baum
executiveBefore we start, I should mention that this isn't in my prepared remarks: this is, I believe, the lengthiest call we have ever conducted. It brings to mind our recent State of the Union, which set a record. Next time, we will certainly make an effort to run this call somewhat more efficiently; we are sorry for how long it lasted, yet I believe it was worth it. I hope everyone listening now has a much clearer understanding of where this company stands and where we are headed across the quarters and years ahead. Throughout the portfolio, we are witnessing real momentum, better access, broader adoption, and strengthening commercial execution. We have a terrific new commercial leadership team. Numerous products are scaling substantially. Important franchises are deepening, and we are observing the first hints of inflection in areas where we have stayed patient and disciplined. Consequently, you hold a business whose revenue is increasingly concentrated in durable, high-value assets, and we have several routes to further growth through other products. Thank you for your ongoing trust in Harrow Health, Inc. We are creating something enduring, lasting, and valuable, and we feel the most thrilling chapter of our story lies ahead. That brings our call to a close. Thank you.
Operator
operatorThank you for your participation. You may now disconnect. Everyone, have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Harrow, Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Harrow, Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Harrow, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.